Foreign News HEALTH INTERNATIONAL NEWS LEISURE NEWS SOCIETY GIST UNITED KINGDOM BEGINS WORLD LARGEST TRIAL OF BLOOD TEST THAT CAN DETECT MORE THAN 50 TYPES OF CANCER By Admin Posted on 2 weeks ago 6 min read 0 0 Share on Facebook Share on Twitter Share on Google+ Share on Pinterest Share on Linkedin CANCER By Aishat Momoh. O. The National Health Service (NHS) is launching the world’s largest trial of a potentially life-saving blood test that can detect more than 50 different types of cancer before symptoms appear. According to Sky News, 140,000 volunteers will be recruited in eight areas across England to try the Galleri test, which is already available in the United States. The test has a high degree of accuracy in detecting cancers that are not routinely screened for, as well as determining where the disease originates in the body. “This quick and simple blood test could mark the beginning of a revolution in cancer detection and treatment here and around the world,” NHS chief executive Amanda Pritchard said. “We have the best opportunity of treating cancer and giving individuals the best possible chance of survival if we can discover it before signs and symptoms appear.” People aged 50 to 77 from all origins and ethnicities will be invited to participate in the NHS trial. They can’t have been diagnosed with cancer within the last three years. Blood samples will be gathered at mobile testing clinics in the following weeks, a year from now, and two years from now. The test searches for chemical changes in genetic code fragments that leak from tumors into the bloodstream, which some malignancies do long before symptoms appear. Ms Pritchard believes the test could help the NHS achieve its goal of catching 75% of tumours at an early stage, when they are easier to treat. It’s particularly good at detecting cancers that are harder to detect early, such as head and neck, bowel, lung, pancreas, and throat cancers. However, it will not be able to detect all malignancies and will not be able to replace NHS screening programs for breast, cervical, and bowel cancer. The trial is being led by Cancer Research UK and the Cancer Prevention Trials Unit at King’s College London, in collaboration with Grail, the company that invented the Galleri test. “The test could be a game-changer for early cancer detection, and we are pleased to be conducting this essential research,” said Professor Peter Sasieni, director of the unit and one of the trial’s primary investigators. “Cancer screening can detect tumors early, when they are more likely to respond to treatment, but not all forms of screening are effective.” Cheshire and Merseyside, Greater Manchester, the North East, West Midlands, East Midlands, East of England, Kent and Medway, and southeast London will be the eight areas engaged in the trial. The first results are due in 2023, and if the test is successful, it might be used as early as 2024. Previous research, published in the journal Annals Of Oncology in June, looked at how the test functioned in 2,823 cancer patients and 1,254 healthy persons. With a false positive rate of only 0.5 percent, it properly diagnosed cancer in 51.5 percent of cases at all stages of the disease. The capacity to obtain a positive test result was twice as high (65.6 percent) for tumors that are not screened for, such as oesophageal, liver, and pancreatic cancers, as it was for tumors that are screened for, such as breast, bowel, cervical, and prostate cancers. Around 55% of blood malignancies were found, and in 88.7% of instances, the cancer’s location was diagnosed.